$ENVA

Enova International stock hits all-time high at 265.6 USD

Enova International Inc. (ENVA) hit an all-time high of $265.60. The stock is up 145.84% over 12 months, with market cap of $6.55B and YTD return of 66.62%. According to InvestingPro, three analysts raised earnings estimates. The company reported Q2 2026 adjusted EPS of $4.31 on $929M revenue, beating projections, and Citizens reiterated a $270 price target.

Original reporting
Published Aug 14, 2026, 2:25 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 15, 2026, 3:41 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$ENVA
Bullish
medium confidence
Mentioned
$ENVA
Relevance
7/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$ENVABullishMed
01

Why it matters

For traders, the actionable element is the combination of a reported Q2 beat (with specific EPS and revenue figures) and the stock reaching a new high, which can influence momentum flows and near-term positioning.

02

Market read

Earnings beat plus record-high pricing can drive momentum and sentiment, but valuation commentary raises the probability of choppier follow-through.

03

What to watch

The text attributes growth to higher originations and improving credit quality, but it provides no detail on underwriting trends, delinquency trajectory, or guidance, which are crucial for sustaining the multiple.

Relevance 7/10Novelty 6/10Timing: post-earnings, after-hours/next-session positioning following the Q2 beat and new high

Background

Enova is described as having strong recent momentum, including an all-time high and an earnings beat, alongside analyst upward revisions and a maintained buy rating.

Company-level read

Ticker impact

$ENVABullishMedium confidence
Context

Enova hit an all-time high at $265.60 and reported Q2 2026 adjusted EPS of $4.31 on $929M revenue, beating estimates.

Expected impact

Likely supports continued upside bias near term, though upside may be capped if valuation concerns dominate after the earnings-driven rally.

Evidence & confidence

Q2 results beat consensus with continued strong EPS growth, and the stock is at a new high; however, the piece also notes fair-value analysis suggesting overvaluation, which can temper follow-through.

Market effects

Reinforces positive sentiment toward consumer and small-business lending originators, where credit quality and origination growth are key drivers.

No specific regional transmission beyond broad US risk-on tone from rate-hike bet reductions.

Limited direct global linkage; primarily a US financials growth/credit-quality narrative.

Counterpoint

The article’s fair-value note implies the stock may already price in strong fundamentals, increasing the risk of mean reversion after the earnings-driven run.

Key entities

  • Enova International Inc.

    Subject of the article, reaching an all-time high and reporting stronger-than-expected Q2 2026 results.

  • Citizens

    Reiterated a Market Outperform rating and maintained a $270 price target for Enova.

Related articles

$ENVAMedAI 8/10

Enova International (ENVA) boosts $300M facility and prices $300.9M consumer loan ABS

Enova International’s subsidiary NC LOC 2024 amended its 2024 revolving facility, increasing the commitment to $300M from $200M, extending the revolving period to Feb. 21, 2029 and maturity to Feb. 21, 2030, and lowering the borrowing rate to SOFR+5.00% from SOFR+5.50%. Enova also priced $300.886M consumer loan ABS (2026-A Notes) with class interest rates 5.88%, 7.68%, and 10.64%.

$OPFIMed

OppFi and Enova Bank Deals Put Lending Under Scrutiny

Attorneys general asked the Federal Reserve, OCC and FDIC to deny banking privileges tied to OppFi’s $130M acquisition of BNCCORP and BNC National Bank and Enova’s proposed acquisition of Grasshopper Bancorp and Grasshopper Bank. AGs allege bank partnerships bypass state loan-rate caps and cite high rates and charge-offs. OppFi and Enova project deposit and revenue synergies and EPS accretion.

$ENVAMed

ENVA Rallies As Enova Tops Q2 And Targets Grasshopper Bank Synergies

Enova International Inc. (NYSE: ENVA) shares rose about 9% after Q2 results and guidance-related optimism. The company reported adjusted EPS of $4.31 vs $3.96 consensus and revenue of $928.9M vs $764M prior year, with operating cash flow of $544M and $531.4M free cash flow. Analysts reportedly raised price targets to $257-$280, citing the Grasshopper Bank acquisition and improving credit metrics.

$ENVAMedAI 8/10

Enova International Stock Jumps After Powerful Q2 Beat

Enova International Inc. (NYSE: ENVA) shares rose about 9% during the week after the company reported Q2 2026 results and raised guidance. Adjusted EPS was $4.31 versus $3.96 expected, with revenue up to $928.9M from $764M. Management cited record $5.5B loans, improving margins, and ongoing share repurchases.

$ENVAMed

ENVA Jumps As Enova Earnings Beat Fuels Bullish Targets

Enova International Inc. (NYSE: ENVA) shares rose about 9% after its Q2 2026 results. The company reported adjusted EPS of $4.31 versus $3.23 a year earlier and revenue of $928.9M versus $764M, alongside a consumer credit outlook. Analysts cited bullish targets of $257 to $280 and support near $230.

$ENVAMedAI 8/10

Enova International Signals Strong Growth and Rising EPS

Enova International (ENVA) reported Q2 results and said consolidated originations rose 27% YoY to nearly $2.3B and total revenue rose 22% to $929M. Adjusted EPS increased 33% YoY to $4.31. Credit metrics improved, with net charge-offs at 7.3%. Management raised Q3 and 2026 guidance and noted the pending Grasshopper Bank deal awaits regulatory approval.